Table 1 Cohort characteristics. Age, gender and dose intervals for each vaccine combination

From: High-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicity

Dose 1

 

AZD

BBIBP

mRNA-1273

Sput-26

Dose 2

Overall, n = 497

Ad5, n = 20

AZD, n = 41

BBIBP, n = 25

mRNA-1273, n = 32

Sput-26, n = 29

AZD, n = 25

BBIBP, n = 40

mRNA-1273, n = 30

Sput-26, n = 33

mRNA-1273, n = 20

Ad5, n = 29

AZD, n = 36

BBIBP, n = 34

mRNA-1273, n = 42

Sput-26, n = 25

Sput-5, n = 36

Age

41.8 ± 15.6

32.6 ± 9.4

50.9 ± 12.9

39.1 ± 10.4

43.4 ± 10.9

46.2 ± 11.5

26.2 ± 13.5

29.1 ± 13.0

26.8 ± 11.8

32.4 ± 14.2

26.9 ± 10.3

39.2 ± 14.8

53.2 ± 11.0

52.1 ± 12.3

54.7±9.2

47.7 ±10.8

49.5 ±13.1

Gender

F

252 (51%)

10 (50%)

21 (51%)

12 (48%)

14 (44%)

14 (48%)

13 (52%)

19 (48%)

16 (53%)

18 (55%)

11 (55%)

20 (69%)

16 (44%)

13 (38%)

23 (55%)

12 (48%)

20 (56%)

M

245 (49%)

10 (50%)

20 (49%)

13 (52%)

18 (56%)

15 (52%)

12 (48%)

21 (52%)

14 (47%)

15 (45%)

9 (45%)

9 (31%)

20 (56%)

21 (62%)

19 (45%)

13 (52%)

16 (44%)

T1 (days after dose 1)

64.8 ± 23.7

73.6 ± 9.6

65.7 ± 6.9

65.2 ± 3.1

66.9 ± 16.9

62.4 ± 7.7

33.3 ± 3.1

45.8 ± 17.6

35.1 ± 4.7

38.9 ± 12.9

32.9 ± 2.8

79.0 ± 12.7

82.9 ± 18.9

85.0 ± 27.0

84.8 ± 17.3

82.4 ± 8.0

83.6 ± 18.4

T2 (days after dose 2)

14.3 ± 1.5 (n = 437)

14.2 ± 0.5 (n = 18)

14.2 ± 0.6 (n = 35)

14.3 ± 0.7 (n = 23)

14.5 ± 2.6 (n = 29)

14.1 ± 0.4 (n = 28)

14.4 ± 0.8 (n = 22)

14.8 ± 1.8 (n = 26)

14.2 ± 0.7 (n = 27)

15.1 ± 2.7 (n = 27)

14.1 ± 0.3 (n = 14)

14.3 ± 0.7 (n = 27)

14.7±3.3 (n = 33)

14.1±0.6 (n = 34)

14.0± 0.0 (n = 39)

14.2± 0.7 (n = 23)

14.1 ± 0.6 (n = 32

T3 (days after dose 2)

28.4 ± 1.2 (n = 420)

29.3 ± 0.9 (n = 19)

28.6 ± 1.6 (n = 30)

28.4 ± 0.9 (n = 20)

28.1 ± 0.8 (n = 27)

28.2 ± 0.9 (n = 27)

28.1 ± 0.3 (n = 22)

28.8 ± 1.6 (n = 26)

28.0 ± 0.0 (n = 23)

28.2 ± 1.4 (n = 26)

28.7 ± 1.4 (n = 13)

29.2 ± 1.6 (n = 26)

28.2 ± 0.9 (n = 31)

28.5 ± 1.7 (n = 34)

28.1 ± 0.3 (n = 38)

28.0 ± 0.0 (n = 23)

28.2 ± 1.1 (n = 35)

  1. Mean ± s.d. number of days and standard deviation after dose 1 or dose 2 were calculated from a subset of the total participants, as indicated below each mean.
Back to article page